===
EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA (news with additional
features)
2024-05-16 / 09:54 CET/CEST
The issuer is solely responsible for the content of this announcement.
Göttingen, Germany, May 16, 2024
Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA

. Exploring advanced technologies to help bring novel therapies to patients faster
. Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, and
predictive design of manufacturing processes, and more
. Future plans include the creation of foundational models based on Sartorius' extensive and unique data
sets, as well as new predictive AI models, tools, and simulations
. Dialogue with regulatory authorities on the use of AI in life sciences announced
The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the
development of new and better therapies, combining Sartorius' in-depth knowledge of life sciences and bioprocessing
with NVIDIA's AI-powered computing platforms and software.
"Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise
with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing
progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our
customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius.
Sartorius has been working with NVIDIA since 2020. The life science group has integrated NVIDIA's technology into its
instruments, enabling edge computing applications of its live-cell imaging platform for commercialized AI assays in the
lab. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to
replace animal models in drug discovery and precision medicine. Sartorius is also using NVIDIA solutions for predictive
bioprocess design and simulation tools for manufacturing innovative therapies.
The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms,
software, and services in the Sartorius ecosystem. Plans involve creating and commercializing powerful foundational
models based on Sartorius' extensive and unique data sets. New predictive AI models, tools, and simulations for
numerous application areas will also be available to Sartorius customers through the NVIDIA Clara suite and the NVIDIA
DGX platform.
In a forward-looking approach to innovation and technology integration in the biopharmaceutical sector, the
collaboration will explore numerous advanced technologies, including the computer-based design and simulation of
complex 3D-bioprinted spheroids and organoids or synthetic biological pathways and organisms designed based on
Sartorius cell lines, to produce novel therapeutic agents and therapies.
A profile of Sartorius
Sartorius (XETRA: SRT3 | SRT) is a leading international partner of life sciences research and biopharmaceutical
manufacturing. With innovative laboratory instruments and consumables, the Group's Lab Products & Services division
focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as
well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on
single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely,
rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60
production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of
complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around
14,600 employees are working for customers around the globe.
Visit our Newsroom or follow us on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com

Additional features:
File: 2024-05-16_Sartorius_Media Release_NVIDIA_Collaboration_en
2024-05-16 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      SARTORIUS AG 

Otto-Brenner-Straße 20
37079 Göttingen
Germany

Phone:        +49.(0)551-308.0 
Fax:          +49.(0)551-308.3289 
E-mail:       info@sartorius.com 
Internet:     www.sartorius.com 
ISIN:         DE0007165607, DE0007165631 
WKN:          716560 , 716563 
Indices:      DAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, 

Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1904837

End of News EQS News Service
===
1904837 2024-05-16 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1904837&application_name=news

END) Dow Jones Newswires

May 16, 2024 03:55 ET (07:55 GMT)